Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 18/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 0.84 |
| ▸ | DRD2 | P14416 | 5/20 | 0.74 |
| ▸ | DRD1 | P21728 | 5/20 | 0.74 |
| ▸ | HTR2A | P28223 | 4/20 | 0.74 |
| ▸ | HTR2C | P28335 | 3/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.74 |
| ▸ | HTR6 | P50406 | 3/20 | 0.74 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | DRD5 | P21918 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4613961 | 0.99 | HTR7 (0.98) | HTR7HTR1ADRD2DRD1HTR2A | |
| Hydrochloric Acid SCHEMBL4613466 | 0.93 | HTR7 (0.86) | HTR7HTR1ADRD2DRD1HTR2A | |
| Hydrochloric Acid SCHEMBL4612274 | 0.92 | HTR7 (0.98) | HTR7HTR1ADRD2DRD1HTR2A | |
| Hydrochloric Acid SCHEMBL4612546 | 0.91 | HTR7 (0.82) | HTR7HTR1ADRD2DRD1HTR2A | |
| SCHEMBL4613162 | 0.86 | HTR7 (1.00) | HTR7HTR1ADRD2DRD1HTR2A | |
| SCHEMBL4612207 | 0.85 | HTR7 (1.00) | HTR7HTR1ADRD2DRD1HTR2A | |
| Hydrochloric Acid SCHEMBL4611865 | 0.84 | HTR7 (0.98) | HTR7HTR1ADRD2DRD1HTR2A | |
| Hydrochloric Acid SCHEMBL4614230 | 0.83 | HTR7 (0.82) | HTR7HTR1ADRD2DRD1HTR2A | |
| SCHEMBL4612355 | 0.83 | HTR7 (1.00) | HTR7HTR1ADRD2DRD1HTR2A | |
| SCHEMBL4612021 | 0.83 | HTR7 (0.82) | HTR7HTR1ADRD2DRD1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751106-B1 | PIPERAZINE DERIVATIVES OF ALKYL OXINDOLES | EGIS GYOGYSZERGYAR NYRT (HU) | 2008-10-29 | — | — | EP | claimed |
| US-20070219209-A1 | Piperazine Derivatives Of Alkyl Oxindoles | GYÓGYSZERGYÁR RT. (HU) | 2007-09-20 | — | — | US | claimed |
| EP-1751106-A1 | PIPERAZINE DERIVATIVES OF ALKYL OXINDOLES | EGIS Gyógyszergyár Nyrt (HU) | 2007-02-14 | — | — | EP | claimed |
| WO-2005108363-A1 | PIPERAZINE DERIVATIVES OF ALKYL OXINDOLES | EGIS GYÓGYSZERGYÁR NYRT. (HU) | 2005-11-17 | — | — | WO | claimed |
| EP-1751106-B1 | PIPERAZINE DERIVATIVES OF ALKYL OXINDOLES | EGIS GYOGYSZERGYAR NYRT (HU) | 2008-10-29 | — | — | EP | disclosed |
| CN-101061094-A | Piperazine derivatives for alkyloxindoles | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2007-10-24 | — | — | CN | disclosed |
| US-20070219209-A1 | Piperazine Derivatives Of Alkyl Oxindoles | GYÓGYSZERGYÁR RT. (HU) | 2007-09-20 | — | — | US | disclosed |
| EP-1751106-A1 | PIPERAZINE DERIVATIVES OF ALKYL OXINDOLES | EGIS Gyógyszergyár Nyrt (HU) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005108363-A1 | PIPERAZINE DERIVATIVES OF ALKYL OXINDOLES | EGIS GYÓGYSZERGYÁR NYRT. (HU) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219209-A1 | Piperazine Derivatives Of Alkyl Oxindoles | TPH2, TPH1, HTR2C | HTR7 30/4885HTR1A 21/4885DRD2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.